Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2012 December;24(4) > Minerva Biotecnologica 2012 December;24(4):155-70

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA BIOTECNOLOGICA

A Journal on Biotechnology and Molecular Biology


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,25


eTOC

 

REVIEWS  FREEfree


Minerva Biotecnologica 2012 December;24(4):155-70

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

The use of probiotics in the end-stage renal disease management

Di Cerbo A. 1, Pezzuto F. 1, Palmieri L. 2, Palmieri B. 1

1 Modena and Reggio Emilia University, General Surgery 1 chair, General Surgery and Surgical Specialties Department, Modena, Italy; 2 Nephrology and Dialysis Division, Modena University Hospital, Modena, Italy


FULL TEXT  


Nowadays kidney transplant or dialysis are the only chances to manage end-stage renal disease (ESRD), which implies a considerable increase of the plasma concentration of uremic wastes such as: creatinine, urea and uric acid. The relevant problem of such invasive and complicated procedures is the high social cost (in 2010, in America, the ESRD social charge has been more than 28 bilions dollars) 1 that prevents many low income countries to adequately assist the renal insufficiency patients. Over the years many studies on uremic wastes removal through the gut lumen have been published with conflictuary results. More recently live probiotics microencapsulation by small indipendent research groups,2-9 focused our attention, in the perspective of selective bacterial flora utilization to enhance the intra-gut lumen catabolism of the impaired kidney derived toxic compounds.

top of page

Publication History

Cite this article as

Corresponding author e-mail